Nephros Announces Fourth Quarter and Record Fiscal Year 2025 Financial Results
Rhea-AI Summary
Nephros (Nasdaq: NEPH) reported fiscal 2025 results with net revenue $18.8M (up 33% YoY) and fourth-quarter revenue of $4.7M (up 22% YoY). The company reported net income $1.2M and Adjusted EBITDA $1.6M for 2025, and ended the year with $5.4M cash and no debt.
Gross margin held at 62% for the year; Q4 margin compressed to 58% due largely to tariffs on imports from Italy (15% since April 2025, reduced to 10% Feb 22, 2026). Company cites growth from programmatic reorders, emergency response, service expansion, and a new Nephros Water Institute.
Positive
- Net revenue +33% YoY to $18.8M
- Net income $1.2M for 2025 (second consecutive profitable year)
- Adjusted EBITDA $1.6M for fiscal 2025
- Cash $5.4M and no debt at year-end
Negative
- Q4 gross margin fell to 58% from 64% due to tariffs
- Cost of goods sold increased 32% YoY to $7.2M
- SG&A rose 17% YoY to $9.0M
News Market Reaction – NEPH
In the Mar 13 session, NEPH declined 7.89%, reflecting a notable negative market reaction. Argus tracked a peak move of +19.1% during that session. Argus tracked a trough of -4.4% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Earnings results | Positive | -11.5% | Strong Q3 2025 growth and profitability with record programmatic sales. |
| Aug 07 | Earnings results | Positive | +35.0% | Q2 2025 revenue up 36% Y/Y and third straight profitable quarter. |
| Nov 07 | Earnings results | Positive | +3.9% | Q3 2024 delivers first profitable quarter with margin improvement. |
| Aug 08 | Earnings results | Negative | -8.2% | Q2 2024 revenue decline and net loss despite improving core programmatic sales. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Across recent earnings, NEPH has often posted positive fundamentals with mixed market reactions: two strong rallies, one mild gain, and one sharp selloff despite solid results, indicating inconsistent alignment between earnings strength and short-term price moves.
Over the last several earnings cycles, Nephros moved from initial profitability in Q3 2024 to multiple consecutive profitable quarters through 2025. Prior updates highlighted accelerating revenue growth, improving gross margins, and stronger cash positions, often tied to expanding programmatic sales and new products. Today’s FY25 release, with 33% full-year revenue growth and a second straight year of positive net income, continues that trajectory of scaling a profitable water-filtration business.
Key Terms
adjusted ebitda financial
gross margin financial
cost of goods sold financial
non-cash stock-based compensation financial
depreciation and amortization financial
tariff regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Full-Year Net Revenue Increased
Reports Second Consecutive Year of Positive Net Income
SOUTH ORANGE, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2025.
Financial Highlights
Fourth Quarter Ended December 31, 2025.
- Net revenue was
$4.7 million , compared to$3.9 million in the fourth quarter of 2024, up22% - Net income was
$62,000 , compared to$349,000 during the same period in 2024 - Adjusted EBITDA was
$131,000 , compared to$481,000 in the fourth quarter of 2024
Year-End 2025
- Net revenue was
$18.8 million , compared to$14.2 million for the year ended December 31, 2024,
up33% - Net income was
$1.2 million , compared with$74,000 in 2024 - Adjusted EBITDA was
$1.6 million , compared with$548,000 in 2024
“2025 was transformational for Nephros,” said Robert Banks, President and Chief Executive Officer. “We delivered
“Our differentiated product portfolio remains at the center of our success. Continued expansion of reorder rates, deployment of additional sales associates, and growth beyond traditional healthcare applications drove meaningful revenue gains in 2025. Further, we extended our long-term supply agreement with our key partner, Medica, ensuring continuity of supply and supporting sustained multi-year growth.”
“We also advanced our service offering through the expansion of installation and replacement capabilities led by Alfred Vargas, Director of Service. The development of these functions in-house has meaningfully reduced barriers to adoption, strengthened customer relationships, and increased opportunities for recurring revenue.”
“Additionally, we launched the Nephros Water Institute, led by Brianne McGuire, Director of Business Development, a major milestone in establishing Nephros as an authority in waterborne pathogen mitigation and facility water safety. The Institute expands our engagement with customers and industry stakeholders while supporting long-term demand for filtration, service, and compliance-driven solutions.”
“Following another record year, we believe our integrated product, service, and education strategy strengthens our competitive position and provides a durable foundation for continued growth and operational scale.”
Financial Performance for the Fourth Quarter and Year Ended December 31, 2025
Net revenue for the years ended December 31, 2025, and 2024 was
Cost of goods sold for the year ended December 31, 2025 was
Gross margin was
Selling, general and administrative expenses for the year ended December 31, 2025 were
Research and development expenses for the years ended December 31, 2025, and 2024 were
Depreciation and amortization expenses for the year ended December 31, 2025, were approximately
Net income for the year ended December 31, 2025 was
Adjusted EBITDA for the year ended December 31, 2025 was
As of December 31, 2025, Nephros had cash and cash equivalents of approximately
Adjusted EBITDA Definition and Reconciliation to GAAP Financial Measures
Adjusted EBITDA is calculated by taking net income (loss) calculated in accordance with generally accepted accounting principles (“GAAP”) and excluding all interest-related expenses and income, tax-related expenses and income, non-recurring expenses and income, and non-cash items, including depreciation, amortization, non-cash inventory write-offs, and non-cash compensation. The following tables present a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure, for the fourth quarter and year to date of the 2025 and 2024 fiscal years:
| (unaudited) | ||||||||||
| 2025 | Three Month Period Ended | Annual | ||||||||
| 3/31/2025 | 6/30/2025 | 9/30/2025 | 12/31/2025 | Totals | ||||||
| (in $ thousands) | ||||||||||
| Net income | 558 | 237 | 337 | 62 | 1,194 | |||||
| Adjustments: | ||||||||||
| Depreciation of property and equipment | 17 | 13 | 12 | 13 | 55 | |||||
| Amortization of other assets | 23 | 20 | 22 | 19 | 84 | |||||
| Interest expense | – | 1 | – | – | 1 | |||||
| Interest income | (13 | ) | (31 | ) | (41 | ) | (54 | ) | (139 | ) |
| Income taxes | 9 | 3 | 12 | |||||||
| Non-cash stock-based compensation | 76 | 71 | 70 | 79 | 296 | |||||
| Non-cash inventory impairments | 6 | 35 | 15 | 12 | 68 | |||||
| Adjusted EBITDA Income | 667 | 355 | 418 | 131 | 1,571 | |||||
| (unaudited) | ||||||||||
| 2024 | Three Month Period Ended | Annual | ||||||||
| 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 | Totals | ||||||
| (in $ thousands) | ||||||||||
| Net (loss) income | (169 | ) | (289 | ) | 183 | 349 | 74 | |||
| Adjustments: | ||||||||||
| Depreciation of property and equipment | 11 | 11 | 12 | 12 | 46 | |||||
| Amortization of other assets | 23 | 24 | 21 | 23 | 91 | |||||
| Interest expense | 1 | – | – | – | 1 | |||||
| Interest income | (25 | ) | (21 | ) | (20 | ) | (28 | ) | (94 | ) |
| Income taxes | 15 | 15 | ||||||||
| Non-cash stock-based compensation | (9 | ) | 35 | 65 | 62 | 153 | ||||
| Non-cash inventory impairments | 73 | 107 | 34 | 48 | 262 | |||||
| Adjusted EBITDA Income (loss) | (95 | ) | (133 | ) | 295 | 481 | 548 | |||
Nephros believes that Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to Nephros’ financial condition and results of operations. Management does not consider Adjusted EBITDA in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of Adjusted EBITDA is that it excludes significant expenses and income that are required by GAAP to be recognized in Nephros’ financial statements. In addition, Adjusted EBITDA is subject to inherent limitations as it reflects the exercise of judgments by management about which expenses and income are excluded or included in determining Adjusted EBITDA. To compensate for these limitations, management presents Adjusted EBITDA in connection with net income loss, the most directly comparable GAAP financial measure. Nephros urges investors to review the reconciliation of Adjusted EBITDA to net income loss and not to rely on any single financial measure to evaluate the business.
Conference Call Today at 4:30pm Eastern Time
Nephros will host a conference call today at 4:30pm ET, during which management will discuss Nephros’ financial results and provide a general business overview.
Participants may dial into the call as follows:
Domestic access: 1 (844) 808-7106
International access: 1 (412) 317-5285
Upon joining, please ask to be joined into the Nephros conference call.
An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page.
Alternatively, a replay of the call may be accessed until March 19th, 2026, at 1 (855) 669-9658 or 1 (412) 317-0088 for international callers and entering replay access code: 3018234
About Nephros
Nephros is committed to improving the human relationship with water through leading, accessible technology. We provide innovative water filtration products and services, along with water-quality education, as part of an integrated approach to water safety. Nephros goods serve the needs of customers within healthcare and commercial markets, offering both proactive and emergency solutions for water management.
For more information about Nephros, please visit nephros.com.
Forward-Looking Statements
This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros’ expected revenue and cash flows for the quarter and year ended December 31, 2025, expected future revenue growth and the timing of such growth, the impact of U.S. tariff policy on future financial performance, the effect of new regulations on future revenue growth, the expected competitive advantages and anticipated impact of new product, service and customer education offerings, and other statements that are not historical facts, including statements that may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including Nephros’ ability to further develop its sales organization and realize increased revenues, the extent to which financial results based on emergency response sales can be outside Nephros’ control, U.S. tariff and trade policy, inflationary factors and other economic and competitive conditions, the availability of capital when needed, dependence on third-party manufacturers and researchers, and regulatory reforms. These and other risks and uncertainties are detailed in Nephros’ reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025, which is expected to be filed on or before March 31, 2026. You should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as of the date of this release, and Nephros does not undertake any responsibility to update any forward-looking statements that it makes, except as may be required by law.
Investor Relations Contacts:
Kirin Smith, President
PCG Advisory, Inc.
(646) 823-8656
ksmith@pcgadvisory.com
Robert Banks, CEO
Nephros, Inc.
(201) 343-5202 x110
robert.banks@nephros.com
| NEPHROS, INC. | ||||||||
| BALANCE SHEETS | ||||||||
| (In thousands, except share and per share amounts) | ||||||||
| (Unaudited) | ||||||||
| ASSETS | December 31, 2025 | December 31, 2024 | ||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 5,400 | $ | 3,760 | ||||
| Accounts receivable, net | 2,414 | 1,781 | ||||||
| Inventory | 3,232 | 2,615 | ||||||
| Prepaid expenses and other current assets | 177 | 142 | ||||||
| Total current assets | 11,223 | 8,298 | ||||||
| Property and equipment, net | 106 | 161 | ||||||
| Lease right-use-of assets | 1,021 | 1,377 | ||||||
| Intangible assets, net | 318 | 349 | ||||||
| Goodwill | 759 | 759 | ||||||
| License and supply agreement, net | 164 | 216 | ||||||
| Other assets | 50 | 50 | ||||||
| TOTAL ASSETS | $ | 13,641 | $ | 11,210 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | 914 | 649 | ||||||
| Accrued expenses | 1,462 | 565 | ||||||
| Current portion of lease liabilities | 391 | 348 | ||||||
| Total current liabilities | 2,767 | 1,562 | ||||||
| Equipment financing, net of current portion | – | – | ||||||
| Lease liabilities, net of current portion | 672 | 1,063 | ||||||
| TOTAL LIABILITIES | 3,439 | 2,625 | ||||||
| STOCKHOLDERS' EQUITY: | ||||||||
| Preferred stock, $.001 par value; 5,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding December 31, 2025 and 2024. | – | – | ||||||
| Common stock, $.001 par value; 40,000,000 shares authorized at December 31, 2025 and 2024; 10,644,268 and 10,544,691 shares issued and outstanding at December 31, 2025 and 2024, respectively | 11 | 11 | ||||||
| Additional paid-in capital | 153,329 | 152,906 | ||||||
| Accumulated deficit | (143,138 | ) | (144,332 | ) | ||||
| TOTAL STOCKHOLDERS' EQUITY | 10,202 | 8,585 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 13,641 | $ | 11,210 | ||||
| NEPHROS, INC. | ||||||||||||||||
| STATEMENTS OF OPERATIONS | ||||||||||||||||
| (In thousands, except share and per share amounts) | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net revenue: | ||||||||||||||||
| Product revenues | $ | 4,621 | $ | 3,849 | $ | 18,234 | $ | 14,035 | ||||||||
| Royalty and other revenues | 108 | 21 | 555 | 127 | ||||||||||||
| Total net revenues | 4,729 | 3,870 | 18,789 | 14,162 | ||||||||||||
| Cost of goods sold | 1,968 | 1,395 | 7,164 | 5,439 | ||||||||||||
| Gross margin | 2,761 | 2,475 | 11,625 | 8,723 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative | 2,316 | 1,872 | 9,000 | 7,676 | ||||||||||||
| Research and development | 395 | 252 | 1,339 | 906 | ||||||||||||
| Depreciation and amortization | 32 | 34 | 140 | 135 | ||||||||||||
| Total operating expenses | 2,743 | 2,158 | 10,479 | 8,717 | ||||||||||||
| Operating income | 18 | 317 | 1,146 | 6 | ||||||||||||
| Other (expense) income: | ||||||||||||||||
| Interest expense | – | – | (1 | ) | (1 | ) | ||||||||||
| Interest income | 54 | 28 | 139 | 94 | ||||||||||||
| Other (expense) income net | (10 | ) | 19 | (78 | ) | (10 | ) | |||||||||
| Total other income: | 44 | 47 | 60 | 83 | ||||||||||||
| Income before income taxes | 62 | 364 | 1,206 | 89 | ||||||||||||
| Income tax expense | – | (15 | ) | (12 | ) | (15 | ) | |||||||||
| Net income | $ | 62 | $ | 349 | $ | 1,194 | $ | 74 | ||||||||
| Net income per common share, basic | $ | 0.01 | $ | 0.03 | $ | 0.11 | $ | 0.01 | ||||||||
| Net income per common share, diluted | $ | 0.01 | $ | 0.03 | $ | 0.11 | $ | 0.01 | ||||||||
| Weighted average common shares outstanding, basic | 10,647,399 | 10,544,353 | 10,612,288 | 10,525,197 | ||||||||||||
| Weighted average common shares outstanding, diluted | 11,205,420 | 10,555,990 | 10,968,063 | 10,609,642 | ||||||||||||
